Eftilagimod Alfa Linked to Significant Overall Survival in Late-Stage Cancer Patients
IMMP sits 46% above its 52-week low of $0.293 on light trading volume (0.2× avg).
Summary
Immutep announced results from a systematic evaluation of five clinical trials for its lead candidate, eftilagimod alfa, showing a statistically significant increase in overall survival (median +7.7 months) in late-stage cancer patients who exhibited immune activation. This analysis provides a crucial mechanistic link between the drug's immune-activating effects and clinical efficacy. The positive scientific finding offers a deeper understanding of eftilagimod alfa's potential, especially following the recent discontinuation of the Phase III TACTI-004 trial due to futility, though this analysis does not include TACTI-004 data. The data will be presented at the ASCO 2026 Annual Meeting on May 30, 2026.
At the time of this announcement, IMMP was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.8M. The 52-week trading range was $0.29 to $3.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.